Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Remonie Seng

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
The Journal of Infectious Diseases|March 10, 2015
High Soluble CD14 Levels at Primary HIV-1 Infection Predict More Rapid Disease ProgressionEvguenia Krastinova, Camille Lecuroux, Carole Leroy, et al.
BMC Infectious Diseases|April 19, 2015
Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?Evguenia Krastinova, Remonie Seng, Jerome Lechenadec, et al.
The Journal of Infectious Diseases|March 7, 2018
Nonreactive Human Immunodeficiency Virus Type 1 Rapid Tests After Sustained Viral Suppression Following Antiretroviral Therapy Initiation During Primary InfectionKarl Stefic, Sophie Novelli, Nadia Mahjoub, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 11, 2008
Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts)Remonie Seng, Cécile Goujard, Loïc Desquilbet, et al.
Plos One|August 13, 2013
Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohortsEvguenia Krastinova, Remonie Seng, Patrick Yeni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 11, 2012
Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapyMarie-Laure Chaix, Remonie Seng, Pierre Frange, et al.
AIDS (London, England)|November 26, 2019
Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infectionRaphael Veil, Isabelle Poizot-Martin, Jacques Reynes, et al.
Annals of Internal Medicine|April 20, 2011
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study, Lauren E Cain, Roger Logan, et al.
Plos One|October 25, 2024
HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983-2015Andrew Atkinson, David Kraus, Nicolas Banholzer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 10, 2017
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological ConditionsEllen C Caniglia, Andrew Phillips, Kholoud Porter, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
The Journal of Infectious Diseases|March 10, 2015
High Soluble CD14 Levels at Primary HIV-1 Infection Predict More Rapid Disease ProgressionEvguenia Krastinova, Camille Lecuroux, Carole Leroy, et al.
BMC Infectious Diseases|April 19, 2015
Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?Evguenia Krastinova, Remonie Seng, Jerome Lechenadec, et al.
The Journal of Infectious Diseases|March 7, 2018
Nonreactive Human Immunodeficiency Virus Type 1 Rapid Tests After Sustained Viral Suppression Following Antiretroviral Therapy Initiation During Primary InfectionKarl Stefic, Sophie Novelli, Nadia Mahjoub, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 11, 2008
Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts)Remonie Seng, Cécile Goujard, Loïc Desquilbet, et al.
Plos One|August 13, 2013
Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohortsEvguenia Krastinova, Remonie Seng, Patrick Yeni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 11, 2012
Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapyMarie-Laure Chaix, Remonie Seng, Pierre Frange, et al.
AIDS (London, England)|November 26, 2019
Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infectionRaphael Veil, Isabelle Poizot-Martin, Jacques Reynes, et al.
Annals of Internal Medicine|April 20, 2011
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study, Lauren E Cain, Roger Logan, et al.
Plos One|October 25, 2024
HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983-2015Andrew Atkinson, David Kraus, Nicolas Banholzer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 10, 2017
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological ConditionsEllen C Caniglia, Andrew Phillips, Kholoud Porter, et al.
Pageof 2